Literature DB >> 26371236

Drug Therapy for Heart Valve Diseases.

Jeffrey S Borer1, Abhishek Sharma2.   

Abstract

Entities:  

Keywords:  drug therapy; heart valve diseases; pharmacology

Mesh：

Substances：

Year:  2015        PMID： 26371236      PMCID： PMC4582425          DOI： 10.1161/CIRCULATIONAHA.115.016006

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  99 in total

1.  Volume-overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in dogs.

Authors:  L J Dell'italia; E Balcells; Q C Meng; X Su; D Schultz; S P Bishop; N Machida; I M Straeter-Knowlen; G H Hankes; R Dillon; R E Cartee; S Oparil
Journal:  Am J Physiol       Date:  1997-08

2.  The natural history of 271 patients with mitral stenosis under medical treatment.

Authors:  K H OLESEN
Journal:  Br Heart J       Date:  1962-05

3.  Effect of enalapril therapy on left ventricular mass and volumes in asymptomatic chronic, severe mitral regurgitation secondary to mitral valve prolapse.

Authors:  M D Tischler; M Rowan; M M LeWinter
Journal:  Am J Cardiol       Date:  1998-07-15       Impact factor: 2.778

4.  Myocardial sympathetic denervation prevents chamber-specific alteration of beta-adrenergic transmembrane signaling in rabbits with heart failure.

Authors:  T Anzai; T Yoshikawa; A Baba; H Nishimura; H Shiraki; K Nagami; M Suzuki; Y Wainai; S Ogawa
Journal:  J Am Coll Cardiol       Date:  1996-11-01       Impact factor: 24.094

5.  Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study.

Authors:  B F Stewart; D Siscovick; B K Lind; J M Gardin; J S Gottdiener; V E Smith; D W Kitzman; C M Otto
Journal:  J Am Coll Cardiol       Date:  1997-03-01       Impact factor: 24.094

6.  Prediction of indications for valve replacement among asymptomatic or minimally symptomatic patients with chronic aortic regurgitation and normal left ventricular performance.

Authors:  J S Borer; C Hochreiter; E M Herrold; P Supino; M Aschermann; D Wencker; R B Devereux; M J Roman; M Szulc; P Kligfield; O W Isom
Journal:  Circulation       Date:  1998-02-17       Impact factor: 29.690

7.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

Authors: 
Journal:  Lancet       Date:  1999-06-12       Impact factor: 79.321

8.  Myocardial beta-adrenergic and muscarinic receptor density in cardiac pressure or volume overload.

Authors:  S Guzzetti; T Mennini; A Cagnotto; P Di Biasi; R Scrofani; S Mezzetti; C Cogliati; S Paglia; A Malliani
Journal:  J Mol Cell Cardiol       Date:  1998-10       Impact factor: 5.000

9.  Vasodilator therapy in chronic asymptomatic aortic regurgitation: enalapril versus hydralazine therapy.

Authors:  M Lin; H T Chiang; S L Lin; M S Chang; B N Chiang; H W Kuo; M D Cheitlin
Journal:  J Am Coll Cardiol       Date:  1994-10       Impact factor: 24.094

10.  Aortic regurgitation complicated by extreme left ventricular dilation: long-term outcome after surgical correction.

Authors:  E Klodas; M Enriquez-Sarano; A J Tajik; C J Mullany; K R Bailey; J B Seward
Journal:  J Am Coll Cardiol       Date:  1996-03-01       Impact factor: 24.094
View more
  11 in total

1.  Aortic Valve Regurgitation: Pathophysiology and Implications for Surgical Intervention in the Era of TAVR.

Authors:  Filippo Ravalli; Alexander P Kossar; Hiroo Takayama; Juan B Grau; Giovanni Ferrari
Journal:  Struct Heart       Date:  2020-01-23

2.  Genes That Escape X Chromosome Inactivation Modulate Sex Differences in Valve Myofibroblasts.

Authors:  Brian A Aguado; Cierra J Walker; Joseph C Grim; Megan E Schroeder; Dilara Batan; Brandon J Vogt; Andrea Gonzalez Rodriguez; Jessica A Schwisow; Karen S Moulton; Robert M Weiss; Donald D Heistad; Leslie A Leinwand; Kristi S Anseth
Journal:  Circulation       Date:  2022-01-10       Impact factor: 29.690

Review 3.  Update on assessment and management of primary cardiac involvement in systemic sclerosis.

Authors:  Vasiliki-Kalliopi Bournia; Christos Tountas; Athanase D Protogerou; Stylianos Panopoulos; Sophie Mavrogeni; Petros P Sfikakis
Journal:  J Scleroderma Relat Disord       Date:  2018-04-04

4.  Utilization and Dose Optimization of Angiotensin-Converting Enzyme Inhibitors among Heart Failure Patients in Southwest Ethiopia.

Authors:  Yirga Legesse Niriayo; Kabaye Kumela; Kidu Gidey; Mulugeta Tarekegn Angamo
Journal:  Biomed Res Int       Date:  2019-04-24       Impact factor: 3.411

5.  Serotonin and catecholamines in the development and progression of heart valve diseases.

Authors:  Elliott Goldberg; Juan B Grau; Jacqueline H Fortier; Elisa Salvati; Robert J Levy; Giovanni Ferrari
Journal:  Cardiovasc Res       Date:  2017-07-01       Impact factor: 10.787

6.  Fibrotic Aortic Valve Stenosis in Hypercholesterolemic/Hypertensive Mice.

Authors:  Yi Chu; Donald D Lund; Hardik Doshi; Henry L Keen; Kevin L Knudtson; Nathan D Funk; Jian Q Shao; Justine Cheng; Georges P Hajj; Kathy A Zimmerman; Melissa K Davis; Robert M Brooks; Mark W Chapleau; Curt D Sigmund; Robert M Weiss; Donald D Heistad
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-01-14       Impact factor: 8.311

7.  MG 53 Protein Protects Aortic Valve Interstitial Cells From Membrane Injury and Fibrocalcific Remodeling.

Authors:  T M Ayodele Adesanya; Melanie Russell; Ki Ho Park; Xinyu Zhou; Matthew A Sermersheim; Kristyn Gumpper; Sara N Koenig; Tao Tan; Bryan A Whitson; Paul M L Janssen; Joy Lincoln; Hua Zhu; Jianjie Ma
Journal:  J Am Heart Assoc       Date:  2019-02-19       Impact factor: 5.501

8.  Transcatheter aortic valve replacements alter circulating serum factors to mediate myofibroblast deactivation.

Authors:  Brian A Aguado; Katherine B Schuetze; Joseph C Grim; Cierra J Walker; Anne C Cox; Tova L Ceccato; Aik-Choon Tan; Carmen C Sucharov; Leslie A Leinwand; Matthew R G Taylor; Timothy A McKinsey; Kristi S Anseth
Journal:  Sci Transl Med       Date:  2019-09-11       Impact factor: 19.319

9.  Impact of renin-angiotensin system inhibitors on long-term clinical outcomes of patients with rheumatic heart disease.

Authors:  Cheng Liu; Yanxian Lai; Deping Wu; Ruibin Fu; Yanfang Li; Hu Li; Tianwang Guan; Yan Shen
Journal:  ESC Heart Fail       Date:  2021-09-20

10.  Network modeling predicts personalized gene expression and drug responses in valve myofibroblasts cultured with patient sera.

Authors:  Jesse D Rogers; Brian A Aguado; Kelsey M Watts; Kristi S Anseth; William J Richardson
Journal:  Proc Natl Acad Sci U S A       Date:  2022-02-22       Impact factor: 12.779
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.